TL;DR:

  • VR-based motor rehabilitation for stroke has strong evidence behind it — meta-analyses consistently show it improves upper limb function when added to conventional therapy, particularly due to the high repetition VR enables
  • Several clinical XR systems (MindMaze, Penumbra REAL, XRHealth) are cleared for medical use in the US; UK adoption lags but NHS pilots are accelerating
  • VR’s main mechanism in rehab is engagement: patients complete significantly more repetitions per session in VR than in conventional exercise, which drives neuroplasticity in motor recovery
  • The practical barriers are infection control (shared headsets), MHRA device classification, and a patient population (elderly, post-stroke) that needs careful user experience design to avoid VR sickness

Rehabilitation is, at its core, a repetition problem. After a stroke damages the motor cortex, recovery requires rebuilding neural pathways through repeated movement — the volume of practice matters as much as the quality. But repetitive exercises are tedious, and compliance drops. Physiotherapy sessions are time-limited. Neuroplasticity has a window.

VR doesn’t solve all of this, but it addresses the engagement and repetition bottleneck remarkably well. Put a patient in an immersive game that requires them to reach, rotate their wrist, or shift their weight, and they’ll often complete three or four times as many repetitions per session as they would doing the same movements on a treatment table — because the VR context gives the movement meaning and provides immediate feedback.

This is the primary mechanism behind VR rehabilitation’s clinical results, and it explains why the evidence is strongest in conditions where repetition volume is a limiting factor: stroke motor recovery, balance disorders, and chronic pain management.

The Clinical Evidence

Stroke upper limb rehabilitation

This is the most-studied application of XR in physical rehabilitation. A 2023 Cochrane systematic review and multiple subsequent meta-analyses found that VR-based upper limb training, when added to conventional rehabilitation, produces statistically significant improvements in arm function and activities of daily living compared to conventional therapy alone.

The effect sizes are modest but clinically meaningful — roughly equivalent to adding additional physiotherapy time, which is exactly what VR provides in practice. For patients in the chronic phase of stroke recovery (more than six months post-stroke), where conventional therapy often plateaus, VR continues to produce improvements.

Upper limb VR rehabilitation systems typically involve:

  • Tracking of arm and hand movement (via the headset’s controllers, external cameras, or gloves)
  • Gamified tasks mapped to therapeutic movements (reaching, grasping, rotating)
  • Adjustable difficulty that responds to patient performance
  • Session logging for therapist review of repetition counts, range of motion, and error patterns

MindMaze (based in Lausanne) has FDA 510(k) clearance for its MindMotion suite of VR rehabilitation software. Clinically deployed in the US and parts of Europe, it’s purpose-built for neurological rehabilitation with evidence across multiple publications from hospital deployments.

Penumbra’s REAL System (approved by FDA for stroke rehabilitation) is a head-mounted VR system with haptic controllers designed for clinical settings. It has a substantial body of peer-reviewed evidence and is deployed in US stroke units and rehabilitation centres.

Balance and vestibular rehabilitation

VR is well-suited to balance training because it can create controlled, adjustable visual challenges that test the vestibular system without the fall risk of real environments. For patients recovering from vestibular disorders (labyrinthitis, BPPV sequelae), central vestibular dysfunction after stroke or TBI, or age-related balance impairment, VR balance training shows consistent benefits.

The immersive environment allows therapists to adjust the visual scene (moving backgrounds, narrowing corridors) to progressively challenge balance without physical risk to the patient.

Phantom limb pain

VR mirror therapy — where a VR system creates a visual representation of the missing limb in the location where it would be — is one of the more remarkable rehabilitation applications. Patients can see and “move” the virtual limb, which can reduce phantom limb pain through a mechanism thought to involve the updating of incorrect body maps in the motor cortex.

Small-to-medium sized clinical trials support this application. It’s not a cure, but for a condition with few effective interventions, the evidence is meaningful and the side effect profile is benign.

Chronic pain

Beyond phantom limb pain, VR distraction has been validated for acute pain management — reducing pain scores during wound dressing changes, burn care, and physiotherapy procedures. AppliedVR’s RelieVRx received FDA authorisation for adjunctive treatment of chronic lower back pain using cognitive behavioural therapy delivered in VR, establishing a regulatory pathway for this application in the US.

Post-operative physiotherapy

Hip and knee replacement rehabilitation requires consistent adherence to specific exercises. VR home rehabilitation programs (where patients use a consumer headset with clinical-grade guidance software) have shown promising adherence rates in trials — patients complete prescribed exercises more reliably when guided through VR than through paper sheets or videos.

Clinical XR Platforms

MindMaze / MindMotion — Clinically validated VR rehabilitation software for neurological recovery. Hospital-deployed, FDA-cleared in the US, CE-marked in Europe. Used in post-stroke, TBI, and multiple sclerosis rehabilitation programmes.

Penumbra REAL System — FDA-cleared immersive VR rehabilitation for upper extremity and balance. Clinical-grade hardware (not a modified consumer headset). Deployed in US rehabilitation hospitals.

XRHealth — Cloud-based platform with multiple therapy applications, FDA-authorised. Can run on consumer headsets (Meta Quest) which reduces hardware cost for clinic deployment.

Accelerate VR / Khymera — UK-founded companies providing VR rehabilitation software designed for NHS deployment. Working through MHRA device registration processes and NICE evaluation pathways.

Realeyes / Healix VR — Platforms used in UK private rehabilitation and some NHS pilot settings for pain management and physiotherapy.

How UK NHS Adoption Works (and Why It’s Slow)

The NHS pathway for adopting XR rehabilitation technology involves several hurdles that don’t exist or are simpler in the US:

MHRA device classification: If VR software makes a therapeutic claim (rather than just providing entertainment), it typically needs to be registered as a medical device with the MHRA. Post-Brexit, UK manufacturers need UKCA marking (the UK equivalent of CE marking for medical devices). US FDA clearance provides some credibility but doesn’t substitute for MHRA registration.

NICE evaluation: The National Institute for Health and Care Excellence (NICE) evaluates whether technologies are cost-effective for NHS use. NICE has published guidance on digital health technologies and is increasingly reviewing XR rehabilitation tools, but the process is lengthy and requires UK-specific health economic evidence.

NHS procurement: Even after regulatory approval and NICE guidance, each NHS trust makes its own procurement decisions. Adoption is fragmented — one trust may have a VR rehabilitation programme while a neighbouring trust doesn’t, based on local clinical champion availability and budget.

NHS Accelerated Access Collaborative (AAC): The NHS England AAC pathway for innovative medical technologies can speed up adoption for technologies with strong evidence bases. Several XR rehabilitation technologies have been considered through this process.

The practical result is that in 2026, UK VR rehabilitation is common in private rehabilitation settings (Bupa, Nuffield, specialist neurological rehabilitation centres) and in research-active NHS trusts, but not yet standard care in community physiotherapy.

Practical Challenges in Clinical Deployment

Infection control

Shared VR headsets in clinical settings require decontamination between patients. The foam face cushions used in consumer headsets are not cleanable to clinical standards and need to be replaced between patients or switched for wipeable silicone covers. Headset bodies can be wiped with hospital-approved disinfectant solutions, but headsets vary in their tolerance of these products and some can degrade rapidly.

Clinical XR manufacturers have designed their products with this in mind — wipeable materials, removable face gaskets, simplified headset hygiene protocols. Consumer headsets used in clinical settings require more active management.

VR sickness in rehabilitation populations

The elderly post-stroke population has higher VR sickness susceptibility than typical VR users. Several factors contribute: slower processing of conflicting visual/vestibular cues, medications that affect balance, and underlying vestibular impairment.

Clinical VR systems address this with:

  • Narrow field of view displays that reduce peripheral motion
  • High refresh rates (90Hz+) and low latency
  • Stationary or minimally moving visual scenes for initial sessions
  • Gradual habituation protocols
  • Short initial session lengths (5–10 minutes) with patient-controlled stopping

In well-designed clinical VR rehabilitation protocols, VR sickness rates are low (under 10% of sessions), but therapist training on recognition and management is important.

The therapist’s role

VR rehabilitation works best as a supplement to, not a replacement for, physiotherapy. The technology increases the repetition volume and provides objective measurement, but the therapist interprets the data, adjusts the therapeutic programme, corrects compensatory movement patterns that VR can miss, and manages patient motivation and safety.

The risk in health system cost-cutting scenarios is that VR gets used as a way to reduce physiotherapy staffing rather than as a tool to extend what physiotherapy can achieve. The evidence base is built on models where VR adds to therapist contact, not replaces it.

What to Expect Looking Forward

Two trends are reshaping clinical XR rehabilitation:

Home rehabilitation: The availability of consumer-grade headsets (Meta Quest 3S, PlayStation VR2, Apple Vision Pro) creates the possibility of supervised home rehabilitation where patients complete VR exercises between clinic visits and therapists review session data remotely. Several systems are now designed for this hybrid model, which could extend rehabilitation access beyond the hospital setting significantly.

AI-guided adaptive therapy: VR rehabilitation systems are integrating machine learning that adjusts exercise difficulty in real time based on patient performance, identifies compensation strategies from motion data, and personalises the therapy programme without requiring constant therapist adjustment. Early systems are in clinical trials; this is likely to be standard in most clinical platforms within two to three years.

Upper limb robotic systems + VR: Combining soft robotic exogloves that assist weak limb movement with VR visual feedback is showing promising results in trials for severe stroke impairment — where the limb has too little voluntary movement for standard VR exercises to work.

The trajectory is clear: XR in physical rehabilitation is moving from research novelty to clinical standard of care for several conditions. The UK pace of adoption will be set by NICE evaluations and NHS procurement cycles, but the private sector and research-active NHS trusts are already showing what standard care will look like.

References